Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes.

The role of saliva in tick feeding. Front Biosci (Landmark Ed) (2009) 2.73

Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers. Genes Dev (2012) 2.22

The involvement of circulating microparticles in inflammation, coagulation and cardiovascular diseases. Can J Cardiol (2010) 1.08

Microvesicles: novel biomarkers for neurological disorders. Front Physiol (2012) 1.04

Systemic markers of inflammation are independently associated with S100B concentration: results of an observational study in subjects with acute ischaemic stroke. J Neuroinflammation (2010) 0.91

Effects of Olive Oil on Markers of Inflammation and Endothelial Function-A Systematic Review and Meta-Analysis. Nutrients (2015) 0.86

Focus on Extracellular Vesicles: Physiological Role and Signalling Properties of Extracellular Membrane Vesicles. Int J Mol Sci (2016) 0.84

Association of clinical and aetiologic subtype of acute ischaemic stroke with inflammation, oxidative stress and vascular function: a cross-sectional observational study. Med Sci Monit (2011) 0.83

Microparticles: a new perspective in central nervous system disorders. Biomed Res Int (2014) 0.82

The Role of Circulating Platelets Microparticles and Platelet Parameters in Acute Ischemic Stroke Patients. J Stroke Cerebrovasc Dis (2015) 0.80

Microparticle Shedding from Neural Progenitor Cells and Vascular Compartment Cells Is Increased in Ischemic Stroke. PLoS One (2016) 0.80

Endothelial dysfunction and procoagulant activity in acute ischemic stroke. J Vasc Interv Neurol (2012) 0.80

Endothelial cell activation markers and delayed cerebral ischaemia in patients with subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry (2006) 0.80

Von Willebrand factor, red cell fragmentation, and disease activity in systemic lupus erythematosus. HSS J (2008) 0.78

Association of E-selectin gene polymorphism (S128R) with ischemic stroke and stroke subtypes. Inflammation (2014) 0.77

Platelet Activation and Clopidogrel Effects on ADP-Induced Platelet Activation in Cats with or without the A31P Mutation in MYBPC3. J Vet Intern Med (2016) 0.75

Circulating endothelial progenitor cells and the risk of vascular events after ischemic stroke. PLoS One (2015) 0.75

Validation of Repeated Endothelial Function Measurements Using EndoPAT in Stroke. Front Neurol (2017) 0.75

Systemic vascular function, measured with forearm flow mediated dilatation, in acute and stable cerebrovascular disease: a case-control study. Cardiovasc Ultrasound (2010) 0.75

Platelet microparticles: a biomarker for recanalization in rtPA-treated ischemic stroke patients. Ann Clin Transl Neurol (2017) 0.75

Peptidylarginine Deiminases as Drug Targets in Neonatal Hypoxic-Ischemic Encephalopathy. Front Neurol (2016) 0.75

Inflammatory Stroke Extracellular Vesicles Induce Macrophage Activation. Stroke (2017) 0.75

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25

Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med (2003) 11.00

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet (2012) 10.30

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (2015) 7.99

Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med (2012) 6.42

Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet (2015) 6.13

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation (2002) 5.79

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet (2010) 5.30

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73

Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation (2012) 4.10

Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology (2008) 3.47

Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol (2005) 3.42

Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions: we need processes in place to follow up suspicions about serious adverse events. Med J Aust (2004) 3.34

Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost (2011) 3.16

Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation (2003) 3.15

Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 3.14

In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. J Clin Endocrinol Metab (2013) 3.11

Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation (2013) 3.02

Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS (2008) 2.83

National Stroke Association guidelines for the management of transient ischemic attacks. Ann Neurol (2006) 2.82

Medical treatment of peripheral arterial disease. JAMA (2006) 2.76

Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation (2013) 2.72

Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation (2004) 2.69

Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med (2004) 2.65

Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol (2012) 2.63

Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56

Aspirin resistance. Lancet (2006) 2.54

Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet (2009) 2.53

Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med (2008) 2.51

Management of antiphospholipid antibody syndrome: a systematic review. JAMA (2006) 2.47

Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation (2010) 2.46

Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med (2006) 2.40

Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals. Lancet (2013) 2.37

Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet (2011) 2.35

Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J (2011) 2.31

Venous thromboembolism: diagnosis and management of pulmonary embolism. Med J Aust (2005) 2.20

Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. Lancet Neurol (2012) 2.19

The Stroke Riskometer(TM) App: validation of a data collection tool and stroke risk predictor. Int J Stroke (2014) 2.18

Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation (2012) 2.18

Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol (2013) 2.17

Body mass index and survival in men and women aged 70 to 75. J Am Geriatr Soc (2010) 2.16

Behavioural intervention for dysphagia in acute stroke: a randomised controlled trial. Lancet Neurol (2006) 2.11

Low molecular weight heparins and heparinoids. Med J Aust (2002) 2.06

Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation (2008) 2.05

Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab (2009) 2.01

Are the national guidelines for health behaviour appropriate for older Australians? Evidence from the Men, Women and Ageing project. Australas J Ageing (2010) 2.01

Retinal microvasculature in acute lacunar stroke: a cross-sectional study. Lancet Neurol (2009) 2.01

The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol (2002) 1.96

Diagnostic strategies to detect glucose intolerance in a multiethnic population. Diabetes Care (2003) 1.93

Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation (2012) 1.91

The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. Eur Heart J (2012) 1.82

Common variants at 6p21.1 are associated with large artery atherosclerotic stroke. Nat Genet (2012) 1.81

Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke (2013) 1.79

Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med (2009) 1.76

Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol (2012) 1.76

Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol (2007) 1.75

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev (2012) 1.72

Prevalence of sexual activity and associated factors in men aged 75 to 95 years: a cohort study. Ann Intern Med (2010) 1.67

150 minutes of vigorous physical activity per week predicts survival and successful ageing: a population-based 11-year longitudinal study of 12 201 older Australian men. Br J Sports Med (2013) 1.67

Dabigatran etexilate: a new oral thrombin inhibitor. Circulation (2011) 1.66

Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J (2008) 1.65

Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J (2005) 1.65

Relationship of anti-60 kDa heat shock protein and anti-cholesterol antibodies to cardiovascular events. Circulation (2002) 1.65

Stroke risk and antithrombotic strategies in atrial fibrillation. Stroke (2010) 1.62

Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood (2012) 1.59

Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis. J Neurol Sci (2010) 1.59

New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.59

The incidence of venous thromboembolism: a prospective, community-based study in Perth, Western Australia. Med J Aust (2008) 1.57

Risk factors, hospital management and outcomes after acute myocardial infarction in South Asian Canadians and matched control subjects. CMAJ (2002) 1.57

Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv (2011) 1.56

Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med (2011) 1.56

Alcohol use and mortality in older men and women. Addiction (2010) 1.55

Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation (2014) 1.54

Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J (2013) 1.53

Beyond unfractionated heparin and warfarin: current and future advances. Circulation (2007) 1.52

Trends in incidence and outcome of stroke in Perth, Western Australia during 1989 to 2001: the Perth Community Stroke Study. Stroke (2008) 1.52

Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. Lancet HIV (2016) 1.51

Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study. Am Heart J (2010) 1.51

Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study. Stroke (2004) 1.50

Translational success stories: development of direct thrombin inhibitors. Circ Res (2012) 1.49

The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. Eur Heart J (2009) 1.49

Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited. Trials (2011) 1.49

Socioeconomic disparities in stroke rates and outcome: pooled analysis of stroke incidence studies in Australia and New Zealand. Med J Aust (2011) 1.48

Cohort Profile: The Health In Men Study (HIMS). Int J Epidemiol (2008) 1.47

Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism? Br J Haematol (2009) 1.46

Methylenetetrahydrofolate reductase polymorphisms and homocysteine-lowering effect of vitamin therapy in Singaporean stroke patients. Stroke (2006) 1.46

Lower plasma testosterone or dihydrotestosterone, but not estradiol, is associated with symptoms of intermittent claudication in older men. Clin Endocrinol (Oxf) (2013) 1.45

Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting. Circ Cardiovasc Interv (2011) 1.45

Pexelizumab does not "complement" percutaneous coronary intervention in patients with ST-elevation myocardial infarction. JAMA (2007) 1.45